Janux Therapeutics (JANX) Equity Average (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Equity Average data on file, last reported at $949.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $949.2 million, down 6.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $949.2 million (down 6.73% YoY), and the FY2025 annual result was $989.8 million, up 44.8% from the prior year.
• Equity Average fell to $949.2 million in Q1 2026 per JANX's latest filing, from $966.7 million in the prior quarter.
• Over five years, Equity Average peaked at $1.0 billion in Q1 2025 and troughed at $305.4 million in Q2 2023.
• A 5-year average of $602.3 million and a median of $500.1 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2023: Equity Average surged 2400.01% in 2022, then declined 12.74% in 2023.
• A 5-year view of Equity Average shows it stood at $326.1 million in 2022, then grew by 6.29% to $346.6 million in 2023, then surged by 142.16% to $839.4 million in 2024, then climbed by 15.16% to $966.7 million in 2025, then decreased by 1.81% to $949.2 million in 2026.
• Business Quant data shows JANX's Equity Average at $949.2 million in Q1 2026, $966.7 million in Q4 2025, and $983.5 million in Q3 2025.